Pfizer forecasts return to high-single-digit revenue growth from 2029
Updated
Updated · The Wall Street Journal · May 5
Pfizer forecasts return to high-single-digit revenue growth from 2029
12 articles · Updated · The Wall Street Journal · May 5
Chief executive Albert Bourla said growth should average high single digits annually through 2033 after Pfizer reported better-than-expected first-quarter results.
He said the outlook reflects clear visibility despite looming patent losses for drugs including Eliquis and Ibrance and the sharp drop in Covid vaccine and treatment sales.
Bourla said a pipeline of about 10 experimental medicines, including obesity drugs, could create new revenue streams in coming years; Pfizer shares rose 0.5% in afternoon trading.
Can Pfizer's billion-dollar bet on weight-loss drugs truly replace its expiring blockbusters and challenge market leaders?
Pfizer claims AI will make chemotherapy obsolete. Is this the future of cancer treatment or just shareholder hype?
Pfizer Q1 2026 Strong Growth and Vyndamax Patent Extension Secure Revenue Stability Through 2031
Overview
Pfizer started 2026 strong with Q1 results driven by growth in Eliquis, Padcev, and Abrysvo, which offset declines in COVID-19 products. A key legal win extended Vyndamax's U.S. patent protection to 2031, stabilizing its revenue through mid-2031 and supporting long-term growth. However, near-term challenges include patent expiries for Eliquis and Ibrance, expected to erode $1.5 billion in 2026 revenue, alongside the ongoing COVID product wind-down. Pfizer is responding with tight expense controls and a $7.7 billion cost optimization program. Strategic acquisitions of Seagen and Metsera bolster oncology and obesity pipelines, with multiple pivotal studies planned, positioning Pfizer for a high-single-digit revenue growth rate starting in 2029.